GTHP — Guided Therapeutics Income Statement
0.000.00%
- $8.19m
- $9.80m
- $0.01m
Annual income statement for Guided Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.102 | 0.081 | 0.013 | 0.098 | 0.007 |
Cost of Revenue | |||||
Gross Profit | 0.143 | 0.02 | -0.068 | 0.036 | 0.002 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1.45 | 1.86 | 3.81 | 3.36 | 2.05 |
Operating Profit | -1.35 | -1.78 | -3.8 | -3.26 | -2.04 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.279 | -2.07 | -4.34 | -3.49 | -2.42 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.279 | -2.07 | -4.34 | -3.49 | -2.42 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.279 | -2.07 | -4.34 | -3.49 | -2.42 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.401 | -2.43 | -4.97 | -3.76 | -2.59 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.01 | -0.225 | -0.139 | -0.077 | -0.046 |